RET Extracellular Domain Human Recombinant

• Description:

  RET Extracellular Domain Human Recombinant _x000D_ Catalog number: B2016866_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 10 µg_x000D_ Molecular Weight or Concentration: 77.5 kDa_x000D_ Supplied as: Solution_x000D_ Applications: a molecular tool for various biochemical applications_x000D_ Storage: -80°C_x000D_ Keywords: Cadherin Family Member 12, Cadherin-related Family Member 16, CDHF12, CDHR16, Hydroxyaryl-protein Kinase, MEN2A,_x000D_ Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ References:_x000D_ 1: Liu Y, Ribeiro OC, Robinson J, Goldman A. Expression and purification of the extracellular domain of wild-type humanRET and the dimeric oncogenic mutant C634R Int J Biol Macromol. 2020 Dec 1;164:1621-1630._x000D_ 2: Cosma MP, Cardone M, Carlomagno F, Colantuoni V. Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism Mol Cell Biol. 1998 Jun;18(6):3321-9._x000D_ 3: Goodman KM, Kjær S, Beuron F, Knowles PP, Nawrotek A, Burns EM, Purkiss AG, George R, Santoro M, Morris EP, McDonald NQ. RET recognition of GDNF-GFRα1 ligand by a composite binding site promotes membrane-proximal self-association Cell Rep. 2014 Sep 25;8(6):1894-1904._x000D_ 4: Pelet A, Geneste O, Edery P, Pasini A, Chappuis S, Atti T, Munnich A, Lenoir G, Lyonnet S, Billaud M. Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease J Clin Invest. 1998 Mar 15;101(6):1415-23._x000D_ 5: Rabes HM. Gene rearrangements in radiation-induced thyroid carcinogenesis Med Pediatr Oncol. 2001 May;36(5):574-82._x000D_ 6: Arthan D, Hong SK, Park JI. Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells Cancer Lett. 2010 Nov 1;297(1):31-41._x000D_ 7: Rosti K, Goldman A, Kajander T. Solution structure and biophysical characterization of the multifaceted signalling effector protein growth arrest specific-1 BMC Biochem. 2015 Feb 28;16:8._x000D_ 8: Edery P, Lyonnet S, Mulligan LM, Pelet A, Dow E, Abel L, Holder S, Nihoul-Fékété C, Ponder BA, Munnich A. Mutations of the RET proto-oncogene in Hirschsprung's disease Nature. 1994 Jan 27;367(6461):378-80._x000D_ 9: Kjaer S, Ibáñez CF. Identification of a surface for binding to the GDNF-GFR alpha 1 complex in the first cadherin-like domain of RET J Biol Chem. 2003 Nov 28;278(48):47898-904._x000D_ 10: Takahashi M, Asai N, Iwashita T, Isomura T, Miyazaki K, Matsuyama M. Characterization of the ret proto-oncogene products expressed in mouse L cells Oncogene. 1993 Nov;8(11):2925-9._x000D_ _x000D_ Products Related to RET Extracellular Domain Human Recombinant can be found at Proteins

• Short Description:

  Catalog Number: B2016866 (10 µg)_x000D_ RET Extracellular Domain Human Recombinant is a high quality specific portion of the RET protein found in humans. RET is a receptor tyrosine kinase that plays a crucial role in cell signaling and development. This product has been used as a molecular tool for various biochemical applications. It has also been used in a wide array of other chemical and immunological applications. Custom bulk amounts of this product are available upon request._x000D_ _x000D_

• Weight:

  0.15

• Length:

  2

• Width:

  0.5

• Height :

  0.5

• CAS Number:

  9000-83-3